JPH11503901A - インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 - Google Patents
インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4Info
- Publication number
- JPH11503901A JPH11503901A JP8514527A JP51452796A JPH11503901A JP H11503901 A JPH11503901 A JP H11503901A JP 8514527 A JP8514527 A JP 8514527A JP 51452796 A JP51452796 A JP 51452796A JP H11503901 A JPH11503901 A JP H11503901A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- polynucleotide
- ice
- lap
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.単離されたポリヌクレオチドであって、以下からなる群より選択されるメン バーを含有するポリヌクレオチド: (a)配列番号2に記載のアミノ酸1〜アミノ酸341を含有するポリペプチド をコードするポリヌクレオチド; (b)配列番号4に記載のアミノ酸1〜アミノ酸277を含有するポリペプチド をコードするポリヌクレオチド; (c)(a)または(b)のポリヌクレオチドにハイブリダイズし得る、およ び少なくとも95%の同一性がある、ポリヌクレオチド;および (d)(a)、(b)、または(c)のポリヌクレオチドのポリヌクレオチド フラグメント。 2.前記ポリヌクレオチドがDNAである、請求項1に記載のポリヌクレオチド。 3.前記ポリヌクレオチドがRNAである、請求項1に記載のポリヌクレオチド。 4.前記ポリヌクレオチドがゲノムDNAである、請求項1に記載のポリヌクレオ チド。 5.単離されたポリヌクレオチドであって、以下からなる群より選択されるメン バーを含有するポリヌクレオチド: (a)ATCC受託番号75875に含まれるDNAにより発現されるアミノ酸配列を有す る成熟ポリペプチドをコードする、ポリヌクレオチド; (b)ATCC受託番号75873に含まれるDNAにより発現されるアミノ酸配列を有す る成熟ポリペプチドをコードする、ポリヌクレオチド; (c)(a)のポリヌクレオチドにハイブリダイズし得、および少なくとも95 %の同一性がある、ポリヌクレオチド;および (d)(a)、(b)、または(c)のポリヌクレオチドのポリヌクレオチド フラグメント。 6.請求項2に記載のDNAを含有するベクター。 7.請求項6に記載のベクターにより遺伝子操作される宿主細胞。 8.ポリペプチドを生成するプロセスであって、前記DNAによりコードされるポ リペプチドが、請求項7に記載の宿主細胞から発現される工程を包含する、プロ セス。 9.請求項6に記載のベクターで、遺伝子操作された細胞を含有する、ポリペプ チドを発現し得る細胞を作製するためのプロセス。 10.ポリペプチドであって、以下からなる群より選択されるポリペプチド: (i)配列番号2の推定アミノ酸配列を有するポリペプチド、およびそれらのフ ラグメント、アナログ、および誘導体;(ii)ATCC受託番号75875のcDNAにより コードされるポリペプチド、および該ポリペプチドのフラグメント、アナログ、 および誘導体;(iii)配列番号4の推定アミノ酸配列を有するポリペプチド、 およびそれらのフラグメント、アナログ、および誘導体;および(iv)ATCC受託 番号75873のcDNAによりコードされるポリペプチド、および該ポリペプチドのフ ラグメント、アナログ、および誘導体。 11.請求項10に記載のポリペプチドの活性化を阻害する、化合物。 12.ICE-LAP-3を必要とする患者を処置するための方法であって、請求項10 に記載のポリペプチドの治療有効量を該患者への投与する工程を包含する、方法 。 13.前記ポリペプチドの治療有効量が、前記ポリペプチドをコードし、インビ ボで該ポリペプチドを発現するDNAを、前記患者に堤供することにより投与され る、請求項12に記載の方法。 14.ICE-LAP-4を必要とする患者を処置するための方法であって、請求項10 に記載のポリペプチドの治療有効量を該患者に投与する工程を包含する、方法。 15.前記ポリペプチドの治療有効量が、前記ポリペプチドをコードし、インビ ボで該ポリペプチドを発現するDNAを、前記患者に堤供することにより投与され る、請求項14に記載の方法。 16.ICE-LAP-3ポリペプチドを阻害する必要を有する患者を処置するための方 法であって、請求項11に記載の該化合物の治療有効量を該患者に投与する工程 を包含する、方法。 17.ICE-LAP-4ポリペプチドを阻害する必要を有する患者を処置するための方 法であって、請求項11に記載の化合物の治療有効量を該患者に投与する工程を 包含する、方法。 18.疾患、または請求項10に記載のポリペプチドの発現に関する疾患に対す る感受性を診断するためのプロセスであって、該ポリペプチドをコードする核酸 配列における変異を決定する工程を包含する、プロセス。 19.宿主由来のサンプルにおいて、請求項10に記載のポリペプチドの存在を 分析する工程を包含する、診断プロセス。 20.請求項10に記載のポリペプチドを阻害する化合物を同定するための方法 であって、該ポリペプチドとその天然の基質および化合物とを、該基質が該ポリ ペプチドにより正常に切断される条件下で接触させる工程、および切断された基 質が存在しないことを検出することにより、該化合物が該ポリペプチドを阻害す るかどうかを決定する工程を包含する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/334,251 US6538121B1 (en) | 1994-11-01 | 1994-11-01 | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
US08/334,251 | 1994-11-01 | ||
PCT/US1995/007235 WO1996013603A1 (en) | 1994-11-01 | 1995-06-06 | INTERLEUKIN-1 β CONVERTING ENZYME LIKE APOPTOSIS PROTEASE-3 AND 4 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002121377A Division JP2003009889A (ja) | 1994-11-01 | 2002-04-23 | インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11503901A true JPH11503901A (ja) | 1999-04-06 |
JP3675828B2 JP3675828B2 (ja) | 2005-07-27 |
Family
ID=23306335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51452796A Expired - Fee Related JP3675828B2 (ja) | 1994-11-01 | 1995-06-06 | インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 |
JP2002121377A Withdrawn JP2003009889A (ja) | 1994-11-01 | 2002-04-23 | インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002121377A Withdrawn JP2003009889A (ja) | 1994-11-01 | 2002-04-23 | インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 |
Country Status (8)
Country | Link |
---|---|
US (5) | US6538121B1 (ja) |
EP (1) | EP0792370B1 (ja) |
JP (2) | JP3675828B2 (ja) |
AT (1) | ATE302850T1 (ja) |
AU (1) | AU2768895A (ja) |
DE (1) | DE69534402T2 (ja) |
ES (1) | ES2247591T3 (ja) |
WO (1) | WO1996013603A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538121B1 (en) * | 1994-11-01 | 2003-03-25 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
US6835555B1 (en) * | 1994-11-01 | 2004-12-28 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
IL114615A0 (en) * | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
US7097972B1 (en) * | 1995-02-13 | 2006-08-29 | Regents Of The University Of Michigan | Method and composition for regulating apoptosis |
EP0822983A4 (en) * | 1995-04-21 | 2004-12-15 | Merck & Co Inc | apopain |
US6399327B1 (en) | 1995-07-16 | 2002-06-04 | Yeda Research And Development Co. Ltd. | Modulators of the function of FAS receptors and other proteins |
AU720077B2 (en) * | 1995-11-03 | 2000-05-25 | Vertex Pharmaceuticals Incorporated | DNA sequences encoding CMH-1, a cysteine protease involved in apoptosis |
US6462175B1 (en) * | 1995-11-13 | 2002-10-08 | Thomas Jefferson University | Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use |
EP0842665A3 (en) * | 1996-11-14 | 2002-12-18 | Smithkline Beecham Corporation | Interleukin-1 beta converting enzyme like apoptotic proteases and their agonists |
US6340740B1 (en) | 1997-08-26 | 2002-01-22 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
US6432628B1 (en) * | 1997-08-26 | 2002-08-13 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
CA2335099A1 (en) | 1998-07-17 | 2000-01-27 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | New caspase homologue |
AU2001288969A1 (en) * | 2000-09-11 | 2002-03-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 7 expression |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2006035445A2 (en) * | 2004-09-29 | 2006-04-06 | Insight Biopharmaceuticals Ltd. | Methods of treating pathologies associated with oxidative stress |
EP3470087A1 (en) | 2009-02-13 | 2019-04-17 | Immunomedics, Inc. | Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
KR20230078823A (ko) | 2012-12-13 | 2023-06-02 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
WO2016057398A1 (en) | 2014-10-07 | 2016-04-14 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
CN111491655A (zh) | 2017-08-07 | 2020-08-04 | 加利福尼亚大学董事会 | 用于生成安全细胞治疗剂的平台 |
WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0533226A3 (en) | 1991-08-16 | 1993-08-18 | Merck & Co. Inc. | Novel chromophore containing compounds |
US5552536A (en) * | 1994-04-08 | 1996-09-03 | Merck Frosst Canada, Inc. | DNA encoding precursor of interleukin-1 beta converting enzyme - related cysteine proteinase III (ice rel-III) |
US6835555B1 (en) * | 1994-11-01 | 2004-12-28 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
US6538121B1 (en) * | 1994-11-01 | 2003-03-25 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
EP0822983A4 (en) * | 1995-04-21 | 2004-12-15 | Merck & Co Inc | apopain |
-
1994
- 1994-11-01 US US08/334,251 patent/US6538121B1/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/462,969 patent/US6087150A/en not_active Expired - Lifetime
- 1995-06-06 WO PCT/US1995/007235 patent/WO1996013603A1/en active IP Right Grant
- 1995-06-06 AT AT95922997T patent/ATE302850T1/de not_active IP Right Cessation
- 1995-06-06 DE DE69534402T patent/DE69534402T2/de not_active Expired - Fee Related
- 1995-06-06 EP EP95922997A patent/EP0792370B1/en not_active Expired - Lifetime
- 1995-06-06 AU AU27688/95A patent/AU2768895A/en not_active Abandoned
- 1995-06-06 JP JP51452796A patent/JP3675828B2/ja not_active Expired - Fee Related
- 1995-06-06 ES ES95922997T patent/ES2247591T3/es not_active Expired - Lifetime
-
1998
- 1998-07-28 US US09/124,934 patent/US6495519B1/en not_active Expired - Lifetime
-
2001
- 2001-07-02 US US09/895,263 patent/US6733981B2/en not_active Expired - Fee Related
-
2002
- 2002-04-23 JP JP2002121377A patent/JP2003009889A/ja not_active Withdrawn
-
2008
- 2008-08-25 US US12/197,977 patent/US20090142329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1996013603A1 (en) | 1996-05-09 |
EP0792370B1 (en) | 2005-08-24 |
US6538121B1 (en) | 2003-03-25 |
US20090142329A1 (en) | 2009-06-04 |
EP0792370A4 (en) | 1997-10-22 |
ATE302850T1 (de) | 2005-09-15 |
AU2768895A (en) | 1996-05-23 |
JP2003009889A (ja) | 2003-01-14 |
DE69534402T2 (de) | 2006-06-29 |
US6495519B1 (en) | 2002-12-17 |
US6087150A (en) | 2000-07-11 |
ES2247591T3 (es) | 2006-03-01 |
US20020076793A1 (en) | 2002-06-20 |
DE69534402D1 (de) | 2005-09-29 |
US6733981B2 (en) | 2004-05-11 |
JP3675828B2 (ja) | 2005-07-27 |
EP0792370A1 (en) | 1997-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3675828B2 (ja) | インターロイキン−1β転換酵素様アポトーシスプロテアーゼ−3および4 | |
US6448042B1 (en) | Human tissue inhibitor of metalloproteinase-4 | |
US6284504B1 (en) | Human DNA ligase III | |
US5869284A (en) | DNA encoding retinotic acid receptor epsilon | |
JP2003088364A (ja) | 血清パラオキソナーゼ | |
US6602984B1 (en) | Human elastase IV | |
US5723311A (en) | Human DNA topoisomerase I α | |
JPH10501985A (ja) | インターロイキン−1β変換酵素様アポトーシスプロテアーゼ−1および2 | |
US20030099971A1 (en) | Epidermal differentiation factor | |
US5747312A (en) | Human AlkB polypeptide | |
US5650313A (en) | Ubiquitin conjugating enzymes 8 and 9 | |
US5695980A (en) | Polynucleotides, vectors, cells and an expression method for human MutT2 | |
US5849286A (en) | Ubiquitin conjugating enzymes 7,8 and 9 | |
JPH09511648A (ja) | スーパーオキシドジスムターゼ−4 | |
US6455274B1 (en) | Human DNA Ligase IV | |
US6835555B1 (en) | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 | |
JPH11501802A (ja) | ユビキチン結合酵素7、8および9 | |
US6255077B1 (en) | Human DNA topoisomerase I α | |
US6630443B2 (en) | Human amine transporter antibodies | |
US20060234342A1 (en) | Human DNA topoisomerase I alpha | |
US5945321A (en) | Ubiquitin conjugating enzymes 7, 8 and 9 | |
JPH11506309A (ja) | ヒトアミン輸送体 | |
JP2002017379A (ja) | 神経伝達物質輸送体 | |
WO2002074907A2 (en) | Methods of modulating surfactant production | |
MXPA97000151A (en) | Elastase iv hum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040709 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041007 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050427 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080513 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090513 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |